Oral semaglutide started at 14mg (Rybelsus, approved for Type 2 diabetes). At that dose, weight loss was meaningful for diabetes but modest by obesity pharmacotherapy standards — roughly 5-7%. OASIS asked the obvious question: what happens at higher doses? The answer repositions oral semaglutide as a serious weight loss tool.
OASIS program overview
| Trial | Population | Doses Tested | Duration | Key Result |
|---|---|---|---|---|
| OASIS-1 | Obesity (no T2D) | 25mg, 50mg | 68 weeks | 50mg: ~17% weight loss |
| OASIS-2 | T2D + obesity | 25mg, 50mg | 68 weeks | HbA1c -1.5 to -2.0% + weight loss |
| OASIS-3 | vs. injectable sema 2.4mg | 50mg vs injection | 68 weeks | Non-inferiority assessment |
| OASIS-4 | Bariatric surgery population | 25mg, 50mg | 68 weeks | Weight loss after prior surgery |
| OASIS-5 | T2D (broader population) | 25mg, 50mg | 52 weeks | Glycemic control focus |
The injectable-to-oral comparison
OASIS-3 is the most commercially important trial: a direct comparison of oral semaglutide 50mg vs. injectable semaglutide 2.4mg. If oral 50mg demonstrates non-inferiority or approaches the injectable's efficacy, it fundamentally changes the value proposition — patients who respond to semaglutide but prefer a daily pill over a weekly injection have a clinically validated alternative.
The ~17% weight loss seen with oral 50mg in OASIS-1 is within striking distance of injectable 2.4mg's 14.9% in STEP 1, though cross-trial comparison is unreliable. OASIS-3's head-to-head design will provide the definitive answer. If the oral dose matches or approaches the injectable, patient preference — not efficacy — becomes the primary determinant of formulation choice.
Dose-response and the 25mg step
Oral semaglutide 25mg produced approximately 12-14% weight loss — substantially more than the 14mg dose (5-7%) and meaningfully less than 50mg (~17%). The 25mg dose may serve as an intermediate option for patients who need more efficacy than 14mg but don't tolerate or don't need 50mg.
This dose flexibility is a practical advantage of the oral formulation: clinicians can titrate through 14mg, 25mg, and 50mg to find the minimum effective dose for each patient. Injectable semaglutide has a narrower dose range (0.25mg to 2.4mg in fixed steps), and the jump from 1.7mg to 2.4mg is the only clinically significant titration decision.
GI tolerability at higher oral doses
Higher oral doses produce more GI adverse events, but the difference between 25mg and 50mg is smaller than the difference between 14mg and 25mg. The GI tolerability plateau suggests that most GI-sensitive patients are identified during the 14mg to 25mg titration, and those who tolerate 25mg generally tolerate 50mg with modest incremental side effects.
Nausea rates at 50mg are approximately 30-35% during titration (vs ~20% at 14mg), resolving to 5-8% during maintenance in most patients. The extended titration schedule — stepping through 3mg, 7mg, 14mg, 25mg, and 50mg over 20+ weeks — is essential for tolerability and should not be compressed.
Oral semaglutide at 25mg and 50mg transforms the oral GLP-1 category from a diabetes treatment with modest weight effects into a competitive obesity pharmacotherapy. The daily dosing requirement remains a persistence disadvantage vs weekly injectable, but for patients who strongly prefer oral medication, the efficacy gap has narrowed to a clinically acceptable range.